Abstract
The management of acute myeloid leukemia (AML) has changed dramatically with the addition of many new agents since 2017. Intensive chemotherapy regimens with or without a stem-cell transplant remain the most effective option for those who can tolerate aggressive therapy. For those who cannot, a combination of oral agents can effectively be used.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 26-30 |
| Number of pages | 5 |
| Journal | Journal of Managed Care Medicine |
| Volume | 26 |
| Issue number | 3 |
| State | Published - 2023 |
ASJC Scopus subject areas
- Health Policy